Insight: Life Sciences Compliance Considerations for 2016

Pharma Compliance Monitor

"Although science continues to outpace the law, it is imperative that compliance infrastructures remain current. Effective compliance programs continue to be top of mind for industry stakeholders. Investors, elected officials, enforcement authorities, government and private payers, and employees themselves continue to demand responsible corporate behavior from health care and life sciences companies, management and directors."

Read the article here.

Related Contacts
Wendy Goldstein Partner, New York